Chronic lymphocytic leukaemia: open trials in South Korea

15 open trials have a site in South Korea. Registry data; only the trial team decides who can take part.

NCT05091424
A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab and a Combined Regimen of Mosunetuzumab and Venetoclax in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia
Trial Treatment · Phase 1 · Hoffmann-La Roche
Seoul National University Hospital, Seoul · Yeouido St. Mary's Hospital, Seoul · Seoul St. Mary's Hospital, Seoul
Registry updated 2026-11-05
NCT06588478
A Study Evaluating the Efficacy and Safety of Pirtobrutinib in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Trial Treatment · Phase 2 · Loxo Oncology, Inc.
Pusan National University Hospital, Busan · Chonnam National University Hwasun Hospital, Hwasun-gun · Seoul National University Hospital, Seoul · The Catholic Univ. of Korea Seoul St. Mary's Hospital, Seoul · The Catholic University of Korea Yeouido St. Mary's Hospital, Seoul · Samsung Medical Center, Seoul
Registry updated 2026-11-04
NCT06788509
A Rollover Study for Continued Study Treatment and Ongoing Safety Monitoring
Trial Treatment · Phase 1 · Janssen Research & Development, LLC
Severance Hospital, Yonsei University Health System, Seoul
Registry updated 2026-11-04
NCT06564038
A Study of AZD0486 Monotherapy or in Combination With Other Anti-Cancer Agents for Mature B-Cell Malignancies
Trial Treatment · Phase 1/2 · AstraZeneca
Busan · Seoul
Registry updated 2026-10-28
NCT04728893
Efficacy and Safety of Nemtabrutinib (MK-1026) in Participants With Hematologic Malignancies (MK-1026-003)
Trial Treatment · Phase 2 · Merck Sharp & Dohme LLC
Severance Hospital Yonsei University Health System (Site 2201), Seoul · Samsung Medical Center (Site 2200), Seoul
Registry updated 2026-10-27
NCT06943872
A Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax Plus Rituximab Treatment In Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CELESTIAL-RRCLL)
Trial Treatment · Phase 3 · BeOne Medicines
Samsung Medical Center, GangnamGu · National Cancer Center (Korea), IlsandongGu GoyangSi · The Catholic University of Korea, Seoul St Marys Hospital, SeochoGu · Severance Hospital Yonsei University Health System, SeodaemunGu · Pusan National University Hospital, Seogu · Seoul National University Bundang Hospital, Seongnam-si · Seoul National University Hospital, Seoul
Registry updated 2026-10-23
NCT05006716
A Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies
Trial Treatment · Phase 1/2 · BeOne Medicines
Samsung Medical Center, GangnamGu · The Catholic University of Korea, Seoul St Marys Hospital, SeochoGu · Severance Hospital Yonsei University Health System, SeodaemunGu · Pusan National University Hospital, Seogu · Seoul National University Hospital, Seoul · Asan Medical Center, SongpaGu
Registry updated 2026-10-05
NCT06846671
A Study of Tacabrutideg (BGB-16673) Compared to Investigator's Choice in Participants With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Both Bruton Tyrosine Kinase (BTK) and B-cell Leukemia/Lymphoma 2 Protein (BCL2) Inhibitors
Trial Treatment · Phase 3 · BeOne Medicines
Samsung Medical Center, GangnamGu · Chonnam National University Hwasun Hospital, HwasunGun · National Cancer Center (Korea), IlsandongGu GoyangSi · Kyungpook National University Hospital, Junggu · The Catholic University of Korea, Seoul St Marys Hospital, SeochoGu · Dong A University Hospital, Seogu · Seoul National University Hospital, Seoul
Registry updated 2026-09-28
NCT06973187
A Study to Evaluate the Safety and Efficacy of Tacabrutideg (BGB-16673) Compared to Pirtobrutinib in Adults With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Trial Treatment · Phase 3 · BeOne Medicines
Gyeongsang National University Hospital, Jinju · The Catholic University of Korea, Seoul St Marys Hospital, SeochoGu · Severance Hospital Yonsei University Health System, SeodaemunGu · Pusan National University Hospital, Seogu · Seoul National University Bundang Hospital, Seongnam-si · Seoul National University Hospital, Seoul
Registry updated 2026-09-28
NCT07277231
A Study to Investigate Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Acalabrutinib in Adults With Previously Untreated Chronic Lymphocytic Leukemia
Trial Treatment · Phase 3 · BeOne Medicines
The Catholic University of Korea, Seoul St Marys Hospital, SeochoGu · Severance Hospital Yonsei University Health System, SeodaemunGu · Seoul National University Bundang Hospital, Seongnam-si · Seoul National University Hospital, Seoul · Asan Medical Center, SongpaGu
Registry updated 2026-09-28
NCT05254743
A Study of Pirtobrutinib (LOXO-305) Versus Ibrutinib in Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
Trial Treatment · Phase 3 · Loxo Oncology, Inc.
Inje Univ Busan Paik Hospital, Busan · The Catholic University of Korea-Seoul St. Mary's Hospital, Seocho-Gu · Samsung Medical Center, Seoul · Seoul National University Hospital, Seoul
Registry updated 2026-08-17
NCT06876649
A Master Protocol to Evaluate the Long-Term Safety of (LY3527727) Pirtobrutinib
Trial Treatment · Phase 4 · Eli Lilly and Company
Seoul National University Hospital, Seoul
Registry updated 2026-03-02
NCT06876662
A Study of (LY3527727) Pirtobrutinib in Participants With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Non-Hodgkin Lymphoma
Trial Treatment · Phase 4 · Eli Lilly and Company
Seoul National University Hospital, Seoul
Registry updated 2026-03-02
NCT07173790
Watch and Wait or Worry and Wait in Indolent Lymphoma
Research · Seoul National University Hospital
Korea UniversityKorea University Guro Hospital, Seoul · Seoul National University Hospital, Seoul · The Catholic University of Korea, Seoul · Samsung Medical Center, Seoul
Registry updated 2025-11-21
NCT04502394
Safety and Efficacy of KRT-232 in Combination With Acalabrutinib in Subjects With R/R DLBCL or R/R CLL
Trial Treatment · Phase 1/2 · Kartos Therapeutics, Inc.
National Cancer Center, Goyang · Gachon University Gil Medical Center, Incheon · Samsung Medical Center, Seoul · Seoul St. Mary's Hospital, Seoul · Severance Hospital, Yonsei University Health System, Seoul · Seoul National University Hospital, Seoul
Registry updated 2022-08-04

All Chronic lymphocytic leukaemia trials and the map

This page is not medical advice. Talk to your doctor before contacting a trial.

Report an error